Launched in early 2022, CoVICIS represents a global approach to combatting the SARS-CoV-2 pandemic, coupling powerful state-of-the-art virologic and immunologic platforms with large genomic surveillance studies and diverse cohorts in Europe and sub-Saharan Africa (SSA).

Professor Puhan joins us to discuss the three prospective cohort studies, including children, adolescents, and adults, based at EBPI that are contributing to the CoVICIS project.

Professor Puhan joins us to discuss the three prospective cohort studies, including children, adolescents, and adults, based at EBPI that are contributing to the CoVICIS project.

The European Health and Digital Executive Agency (HaDEA) has published three Prior Information Notices (PINs) under […]

In February, the Africa CDC, Gavi, the Regionalized Vaccine Manufacturing Collaborative convened […]

On 30 January, in a significant step forward in Europe’s ability to […]

The EU’s Innovative Health Initiative (IHI) has issued a single-stage, applicant-driven Call for Proposals aligned […]

Check out this selection of four articles from CoVICIS researchers over the […]

The European Commission’s Health Emergency Preparedness and Response Authority (HERA) has signed […]

Since 1 January 2025, the first six EU reference laboratories (EURLs) for […]

On 2 December 2024, the European Commission’s Health Emergency Preparedness and Response […]

On 29 November 2024, UK Research and Innovation published a process map to help researchers use […]

On 27 November 2024, the European Parliament approved a new European College […]

Global Health EDCTP3 invites the submission of abstracts and scientific symposia to be presented […]

HERA has commissioned a comprehensive Study mapping structures with relevant mandates, tasks, and […]

The European Commission adopted has adopted an Implementing Regulation for the management […]

In collaboration with the European Investment Bank (EIB), the Health Emergency Preparedness and Response […]

The European Commission seeks nominations of scientists to be shortlisted for membership on […]

The European and Developing countries Clinical Trial Partnership (EDCTP3) seeks expressions of […]

Africa’s two leading public health institutions are seeking 1 billion USD for […]

The Africa Centres for Disease Control (CDC) and the Coalition for Epidemic […]

The European Commission has designated the first six European reference laboratories (EURLs) […]

CoVICIS, a collaborative effort spanning three countries—South Africa, Italy, and Switzerland— has […]

In February, the European Commission’s Health Emergency Preparedness and Response Authority (HERA) […]

As CoVICIS enters its third year of implementation, the CoVICIS study teams continue conducting cutting edge research in Europe and sub-Saharan Africa on SARS-CoV-2 and its implications for infectious disease, key populations and possible future pandemics.

Launched in early 2022, CoVICIS represents a global approach to combatting the SARS-CoV-2 pandemic, coupling powerful state-of-the-art virologic and immunologic platforms with large genomic surveillance studies and diverse cohorts in Europe and sub-Saharan Africa (SSA).

Professor Puhan joins us to discuss the three prospective cohort studies, including children, adolescents, and adults, based at EBPI that are contributing to the CoVICIS project.

Professor Giuseppe Pantaleo spoke with Vittoria D’Alessio from Horizon Magazine to discuss the ongoing work of researchers to monitor populations for new variants of concern. The article features a profile of CoVICIS and the EU-funding COVIRNA project which is devising a test to predict who is most likely to develop cardiovascular complications.

Launched in early 2022, CoVICIS represents a global approach to combatting the SARS-CoV-2 pandemic, coupling powerful state-of-the-art virologic and immunologic platforms with large genomic surveillance studies and diverse cohorts in Europe and sub-Saharan Africa (SSA).

Prof Williamson joins us to discuss the impressive surveillance work being conducted in South Africa and some of the insights into future work to investigate the role of the HIV epidemic in the emergence of variants of concern.